Variable | Category | No. of patients | P value by log-rank test | HRa | 95% CIb | P value by Cox proportional hazards |
---|---|---|---|---|---|---|
Gender | Male | 62 | 0.1288 | Â | Â | Â |
 | Female | 34 |  |  |  |  |
Age | < 65 | 45 | 0.8967 | Â | Â | Â |
 | ≥ 65 | 51 |  |  |  |  |
Location | Head | 73 | 0.8589 | Â | Â | Â |
 | Body-Tail | 23 |  |  |  |  |
Histological differentiation | Well | 8 | 0.2069 | Â | Â | Â |
 | Moderate + Poor | 77 |  |  |  |  |
Tumor stage | T1 + T2 | 10 | 0.1996 |  |  |  |
 | T3 + T4 | 86 |  |  |  |  |
Nodal stage | N0 | 63 | 0.0039 | 2.20 | 1.33-3.80 | 0.0020 |
 | N1 | 33 |  |  |  |  |
NCCN criteria | Resectable | 50 | 0.0339 | 1.40 | 0.90-2.21 | 0.1419 |
 | Borderline resectable | 46 |  |  |  |  |
Preoperative CA19-9 | < 37 U/mL | 25 | 0.3444 | Â | Â | Â |
 | ≥ 37 U/mL | 71 |  |  |  |  |
Postoperative CA19-9 | < 37 U/mL | 57 | 0.0082 | 1.92 | 1.21-3.04 | 0.0062 |
 | ≥ 37 U/mL | 39 |  |  |  |  |
Adjuvant chemotherapy | Gemcitabine | 58 | 0.4201 | Â | Â | Â |
 | Others | 38 |  |  |  |  |
Nm23/NDPK-A status | Negative | 23 | 0.0103 | 1.97 | 1.16-3.56 | 0.0110 |
 | Positive | 73 |  |  |  |  |